BDII

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 29, 2024
PD, Research, New Drug Application, TRD, GHRS, FDA, BDII, Food, EPO, Rat, Psychiatry, Patent, PPD, Patient, IDR, DSM-IV codes, Clinical trial, Insurance, Psychotherapy, G&A, MDD, IND, European Patent Convention, Pharmaceutical industry

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.
  • As announced in November 2023, both trials were recruiting slower than anticipated, in part due to the closure, for business reasons, of one of the two sites activated in each trial.
  • Subsequently, we have implemented measures to strengthen recruitment of both trials, including the addition of further clinical trial sites.
  • For the trial in patients with PPD (GH001-PPD-203), we now expect completion and availability of top-line data in the third quarter of 2024.

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 10, 2022
GLOBE, BDII, Forward-looking statement, IND, Form 20-F, Nasdaq, Food, TRD, PPD, IDR, Annual report, Research, MADRS, Postpartum depression, Bipolar II disorder, G&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, 5-Methoxy-N,N-diisopropyltryptamine, Psychiatry, U.S. Securities and Exchange Commission, Grammatical mood, Clinical trial, Patient, GHRS, Insurance, FDA, Pharmaceutical industry

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.

Key Points: 
  • DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.
  • Cash was $256.9 million as of September 30, 2022, compared to $276.8 million as of December 31, 2021.
  • R&D expenses were $4.6 million for the quarter ended September 30, 2022, compared to $2.6 million for the same quarter in 2021.
  • G&A expenses were $2.0 million for the quarter ended September 30, 2022, compared to $2.1 million for the same quarter in 2021.

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 23, 2022
Research, Psychiatry, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Insurance, Lists of diseases, Postpartum depression, Food, Grammatical mood, U.S. Securities and Exchange Commission, Bipolar II disorder, GLOBE, IDR, 5-Methoxy-N,N-diisopropyltryptamine, Nasdaq, FDA, TRD, GHRS, G&A, Clinical trial, Annual report, Form 20-F, BDII, Forward-looking statement, PPD, Patient, MADRS, Pharmaceutical industry

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.

Key Points: 
  • DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.
  • Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021.
  • R&D expenses were $4.2 million for the quarter ended June 30, 2022, compared to $2.0 million for the same quarter in 2021.
  • G&A expenses were $2.5 million for the quarter ended June 30, 2022, compared to $0.7 million for the same quarter in 2021.